Answers are grounded in this paper and cite their sources.
Real-world study demonstrates that zanubrutinib improves outcomes in elderly patients with CLL, indicating its potential preference over other treatments.
This real-world study demonstrated that zanubrutinib was associated with longer TTD, lower discontinuation rates, and less HCRU compared to acalabrutinib or ibrutinib in older CLL patients aged ≥65 years.
No takes yet. Share an insight, caveat, or question.
Ailawadhi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: